TrialNature medicine2024

Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Steven M Horwitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.